The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...

Successful program buildout prioritizes defined patient flow, infusion access, cold-chain capabilities, and accountability ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells to target tumors. TIL therapy, now FDA-approved for solid tumors, shows ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Universal, off‑the‑shelf CAR‑T cell therapies using gene‑edited donor T cells are beginning ...

Spina bifida is a type of neural tube defect, meaning that a fetus’ developing spine and spinal cord don’t fully form and ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing. The oversubscribed financing round was backed by more than 15 investors, ...